Why the study?
Are sympathomimetic amines with direct myocardial actions more suitable than those without for treating shock following myocardial infarction?
Are sympathomimetic amines with direct myocardial actions more suitable than those without for treating shock following myocardial infarction?
Sympathomimetic amines with direct myocardial actions are preferred for cardiogenic shock post-MI due to inadequate myocardial contractility.
Answers are grounded in this paper and cite their sources.
May guide sympathomimetic selection in post-MI shock; leaves open need for randomized confirmation.
Almost every drug used in the treatment of myocardial infarction accompanied by shock can have serious adverse effects. Inadequate myocardial contractility apparently is at least partly responsible for the hypotension. Accordingly, sympathomimetic amines having direct myocardial actions (norepinephrine, mephentermine, metaraminol) appear to be more suitable than amines having little or no myocardial effect (methoxamine, phenylephrine). However, therapy must be tailored to individual needs; the amines are not interchangeable.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (1965) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: